Ubiquitin–proteasome system dysfunction in Parkinson’s disease: current evidence and controversies

References

• Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology68(5), 384–386 (2007).
   PubMed Web of Science ®Google Scholar
• Litvan I, Halliday G, Hallett M et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J. Neuropathol. Exp. Neurol.66(4), 251–257 (2007).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Post mortem studies in Parkinson’s disease – is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl.56, 1–29 (1999).
   PubMedGoogle Scholar
• Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson’s disease and parkinsonism. Expert Rev. Neurother.7(6), 657–666 (2007).
   PubMedGoogle Scholar
• Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest.116(7), 1744–1754 (2006).
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays22(5), 442–451 (2000).
   PubMed Web of Science ®Google Scholar
• Hershko A, Ciechanover A. The ubiquitin system. Ann. Rev. Biochem.67, 425–479 (1998).
   PubMed Web of Science ®Google Scholar
• Pickart CM. Mechanisms underlying ubiquitination. Ann. Rev. Biochem.70, 503–533 (2001).
   PubMed Web of Science ®Google Scholar
• Peng J, Schwartz D, Elias JE et al. A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol.21(8), 921–926 (2003).
   PubMed Web of Science ®Google Scholar
• Pickart CM. Ubiquitin in chains. Trends Biochem. Sci.25(11), 544–548 (2000).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science315(5809), 201–205 (2007).
   PubMed Web of Science ®Google Scholar
• Alam ZI, Daniel SE, Lees AJ et al. A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J. Neurochem.69(3), 1326–1329 (1997).
   PubMed Web of Science ®Google Scholar
• Forno LS. The Lewy body in Parkinson’s disease. Adv. Neurol.45, 35–43 (1987).
   PubMedGoogle Scholar
• Lewy FH. Paralysis agitans. I. Pathologische Anatomie. Lewandowski M (Ed.). Springer, Berlin, Germany 920–933 (1912).
   Google Scholar
• Kwak S, Masaki T, Ishiura S, Sugita H. Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains. Neurosci. Lett.128(1), 21–24 (1991).
   Google Scholar
• Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. (Berl.)75(4), 345–353 (1988).
   PubMed Web of Science ®Google Scholar
• Fergusson J, Landon M, Lowe J et al. Pathological lesions of Alzheimer’s disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci. Lett.219(3), 167–170 (1996).
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature392(6676), 605–608 (1998).
   PubMed Web of Science ®Google Scholar
• Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem.275(46), 35661–35664 (2000).
   PubMed Web of Science ®Google Scholar
• Shimura H, Hattori N, Kubo S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet.25(3), 302–305 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao J, Chung KK et al. Parkin functions as an E2-dependent ubiquitin–protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA97(24), 13354–13359 (2000).
   PubMed Web of Science ®Google Scholar
• Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinson’s disease. Nature395(6701), 451–452 (1998).
   PubMed Web of Science ®Google Scholar
• Wilkinson KD. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J.11(14), 1245–1256 (1997).
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM et al. α-synuclein in Lewy bodies. Nature388(6645), 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Engelender S, Igarashi S et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet.10(9), 919–926 (2001).
   PubMed Web of Science ®Google Scholar
• Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci.21(24), 9549–9560 (2001).
   PubMed Web of Science ®Google Scholar
• Chen L, Thiruchelvam MJ, Madura K, Richfield EK. Proteasome dysfunction in aged human α-synuclein transgenic mice. Neurobiol. Dis.23(1), 120–126 (2006).
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J et al. alpha-synuclein locus triplication causes Parkinson’s disease. Science302(5646), 841 (2003).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol.179(1), 38–46 (2003).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci. Lett.297(3), 191–194 (2001).
   PubMed Web of Science ®Google Scholar
• Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem.278(45), 44405–44411 (2003).
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Vigouroux S, Wong H et al. Brain proteasomal function in sporadic Parkinson’s disease and related disorders. Ann. Neurol.51(6), 779–782 (2002).
   PubMed Web of Science ®Google Scholar
• Grunblatt E, Mandel S, Jacob-Hirsch J et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin–proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm.111(12), 1543–1573 (2004).
   PubMed Web of Science ®Google Scholar
• Reinheckel T, Ullrich O, Sitte N, Grune T. Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch. Biochem. Biophys.377(1), 65–68 (2000).
   PubMed Web of Science ®Google Scholar
• Bulteau AL, Lundberg KC, Humphries KM et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem.276(32), 30057–30063 (2001).
   PubMed Web of Science ®Google Scholar
• Keller JN, Dimayuga E, Chen Q et al. Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int. J. Biochem. Cell Biol.36(12), 2376–2391 (2004).
   PubMed Web of Science ®Google Scholar
• Zeng BY, Medhurst AD, Jackson M, Rose S, Jenner P. Proteasomal activity in brain differs between species and brain regions and changes with age. Mech. Ageing Dev.126(6–7), 760–766 (2005).
   Google Scholar
• Betarbet R, Canet-Aviles RM, Sherer TB et al. Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system. Neurobiol. Dis.22(2), 404–420 (2006).
   PubMed Web of Science ®Google Scholar
• Wang XF, Li S, Chou AP, Bronstein JM. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson’s disease. Neurobiol. Dis.23(1), 198–205 (2006).
   PubMed Web of Science ®Google Scholar
• Wang C, Ko HS, Thomas B et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum. Mol. Genet.14(24), 3885–3897 (2005).
   PubMed Web of Science ®Google Scholar
• Fornai F, Schluter OM, Lenzi P et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin–proteasome system and α-synuclein. Proc. Natl Acad. Sci. USA102(9), 3413–3418 (2005).
   PubMed Web of Science ®Google Scholar
• Zeng BY, Iravani MM, Lin ST et al. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur. J. Neurosci.23(7), 1766–1774 (2006).
   PubMed Web of Science ®Google Scholar
• Zafar KS, Inayat–Hussain SH, Ross D. A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132. J. Neurochem.102(3), 913–921 (2007).
   PubMed Web of Science ®Google Scholar
• Rideout HJ, Lang-Rollin IC, Savalle M, Stefanis L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem.93(5), 1304–1313 (2005).
   PubMed Web of Science ®Google Scholar
• Biasini E, Fioriti L, Ceglia I et al. Proteasome inhibition and aggregation in Parkinson’s disease: a comparative study in untransfected and transfected cells. J. Neurochem.88(3), 545–553 (2004).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Mytilineou C, Jnobaptiste R et al. Impairment of the ubiquitin–proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem.81(2), 301–306 (2002).
   Google Scholar
• Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci.3(12), 932–942 (2002).
   PubMed Web of Science ®Google Scholar
• Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res.55(6), 659–665 (1999).
   PubMed Web of Science ®Google Scholar
• LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med.11(11), 1214–1221 (2005).
   PubMed Web of Science ®Google Scholar
• Pawlyk AC, Giasson BI, Sampathu DM et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem.278(48), 48120–48128 (2003).
   PubMed Web of Science ®Google Scholar
• Chung KK, Thomas B, Li X et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science304(5675), 1328–1331 (2004).
   PubMed Web of Science ®Google Scholar
• Yao D, Gu Z, Nakamura T et al. Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl Acad. Sci. USA101(29), 10810–10814 (2004).
   PubMed Web of Science ®Google Scholar
• Wong ES, Tan JM, Wang C et al. Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem.282(16), 12310–12318 (2007).
   PubMedGoogle Scholar
• Feany MB, Pallanck LJ. Parkin: a multipurpose neuroprotective agent? Neuron38(1), 13–16 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem.278(24), 22044–22055 (2003).
   PubMed Web of Science ®Google Scholar
• Petrucelli L, O’Farrell C, Lockhart PJ et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron36(6), 1007–1019 (2002).
   PubMed Web of Science ®Google Scholar
• Cookson MR, Lockhart PJ, McLendon C et al. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet.12(22), 2957–2965 (2003).
   PubMed Web of Science ®Google Scholar
• Gu WJ, Corti O, Araujo F et al. The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol. Dis.14(3), 357–364 (2003).
   PubMedGoogle Scholar
• Wang C, Tan JM, Ho MW et al. Alterations in the solubility and intracellular localization of parkin by several familial Parkinson’s disease-linked point mutations. J. Neurochem.93(2), 422–431 (2005).
   PubMed Web of Science ®Google Scholar
• Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U, Tatzelt J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J. Biol. Chem.278(47), 47199–47208 (2003).
   PubMed Web of Science ®Google Scholar
• Fornai F, Lenzi P, Gesi M et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci.23(26), 8955–8966 (2003).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann. Neurol.56(1), 149–162 (2004).
   PubMed Web of Science ®Google Scholar
• Snyder H, Mensah K, Theisler C et al. Aggregated and monomeric alpha-synuclein bind to the S6´ proteasomal protein and inhibit proteasomal function. J. Biol. Chem.278(14), 11753–11759 (2003).
   PubMed Web of Science ®Google Scholar
• Choi P, Snyder H, Petrucelli L et al. SEPT5_v2 is a parkin-binding protein. Brain Res. Mol. Brain Res.117(2), 179–189 (2003).
   PubMedGoogle Scholar
• Imai Y, Soda M, Inoue H et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell105(7), 891–902 (2001).
   PubMed Web of Science ®Google Scholar
• Staropoli JF, McDermott C, Martinat C et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron37(5), 735–749 (2003).
   PubMed Web of Science ®Google Scholar
• Ko HS, von Coelln R, Sriram SR et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci.25(35), 7968–7978 (2005).
   PubMed Web of Science ®Google Scholar
• Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J. Biol. Chem.281(24), 16193–16196 (2006).
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Carrard G, Michel PP et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease. J. Neurochem.86(5), 1297–1307 (2003).
   PubMed Web of Science ®Google Scholar
• Jha N, Kumar MJ, Boonplueang R, Andersen JK. Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson’s disease? J. Neurochem.80(4), 555–561 (2002).
   Google Scholar
• Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol.3(2), 112–121 (2002).
   PubMed Web of Science ®Google Scholar
• Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature387(6630), 299–303 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl Acad. Sci. USA98(15), 8662–8667 (2001).
   PubMed Web of Science ®Google Scholar
• Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J. Biol. Chem.275(28), 21648–21652 (2000).
   PubMed Web of Science ®Google Scholar
• Piccioli P, Porcile C, Stanzione S et al. Inhibition of nuclear factor-κB activation induces apoptosis in cerebellar granule cells. J. Neurosci. Res.66(6), 1064–1073 (2001).
   PubMed Web of Science ®Google Scholar
• Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ.13(6), 951–961 (2006).
   PubMed Web of Science ®Google Scholar
• Mihara M, Erster S, Zaika A et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell11(3), 577–590 (2003).
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science303(5660), 1010–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Nakaso K, Yoshimoto Y, Yano H, Takeshima T, Nakashima K. p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells. Neurosci. Lett.354(3), 213–216 (2004).
   PubMed Web of Science ®Google Scholar
• Nair VD, McNaught KS, Gonzalez-Maeso J, Sealfon SC, Olanow CW. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem.281(51), 39550–39560 (2006).
   PubMed Web of Science ®Google Scholar
• Li X, Yang D, Li L et al. Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures. Neurochem. Int.50(7–8), 959–965 (2007).
   PubMed Web of Science ®Google Scholar
• Paschen W. Role of calcium in neuronal cell injury: which subcellular compartment is involved? Brain Res. Bull.53(4), 409–413 (2000).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Bjorklund LM, Belizaire R et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport13(11), 1437–1441 (2002).
   PubMedGoogle Scholar
• Miwa H, Kubo T, Suzuki A, Nishi K, Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett.380(1–2), 93–98 (2005).
   PubMedGoogle Scholar
• Bove J, Zhou C, Jackson-Lewis V et al. Proteasome inhibition and Parkinson’s disease modeling. Ann. Neurol.60(2), 260–264 (2006).
   PubMed Web of Science ®Google Scholar
• Kordower JH, Kanaan NM, Chu Y et al. Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys. Ann. Neurol.60(2), 264–268 (2006).
   PubMed Web of Science ®Google Scholar
• Manning-Bog AB, Reaney SH, Chou VP et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol.60(2), 256–260 (2006).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Cleeter MW, Muddle JR et al. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol.60(2), 253–255 (2006).
   PubMedGoogle Scholar
• Zeng BY, Bukhatwa S, Hikima A, Rose S, Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol.60(2), 248–252 (2006).
   Google Scholar
• Beal F, Lang A. The proteasomal inhibition model of Parkinson’s disease: “boon or bust”? Ann. Neurol.60(2), 158–161 (2006).
   PubMedGoogle Scholar
• McNaught KS, Olanow CW. Proteasome inhibitor-induced model of Parkinson’s disease. Ann. Neurol.60(2), 243–247 (2006).
   PubMedGoogle Scholar
• Landau AM, Kouassi E, Siegrist-Johnstone R, Desbarats J. Proteasome inhibitor model of Parkinson’s disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov. Disord.22(3), 403–407 (2007).
   Google Scholar
• Donohue TM Jr, Kharbanda KK, Casey CA, Nanji AA. Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease. Alcohol Clin. Exp. Res.28(8), 1257–1263 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Fleming SM, Palacino JJ et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem.278(44), 43628–43635 (2003).
   PubMed Web of Science ®Google Scholar
• Itier JM, Ibanez P, Mena MA et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet.12(18), 2277–2291 (2003).
   PubMed Web of Science ®Google Scholar
• Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl Acad. Sci. USA102(6), 2174–2179 (2005).
   PubMed Web of Science ®Google Scholar
• Von Coelln R, Thomas B, Savitt JM et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl Acad. Sci. USA101(29), 10744–10749 (2004).
   PubMed Web of Science ®Google Scholar
• Palacino JJ, Sagi D, Goldberg MS et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem.279(18), 18614–18622 (2004).
   PubMed Web of Science ®Google Scholar
• Darios F, Corti O, Lucking CB et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet.12(5), 517–526 (2003).
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Mitsui T, Kunishige M, Matsumoto T. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem. Biophys. Res. Commun.348(3), 787–793 (2006).
   PubMed Web of Science ®Google Scholar
• Perez FA, Curtis WR, Palmiter RD. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci.6, 71 (2005).
   Google Scholar
• Casarejos MJ, Menendez J, Solano RM et al. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem.97(4), 934–946 (2006).
   PubMed Web of Science ®Google Scholar
• Lockhart PJ, O’Farrell CA, Farrer MJ. It’s a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG). Mov. Disord.19(1), 101–104 (2004).
   PubMed Web of Science ®Google Scholar
• Lorenzetti D, Antalffy B, Vogel H et al. The neurological mutant quaking(viable) is Parkin deficient. Mamm. Genome15(3), 210–217 (2004).
   Google Scholar
• Saigoh K, Wang YL, Suh JG et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet.23(1), 47–51 (1999).
   PubMed Web of Science ®Google Scholar
• Greene JC, Whitworth AJ, Kuo I et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA100(7), 4078–4083 (2003).
   PubMed Web of Science ®Google Scholar
• Cha GH, Kim S, Park J et al. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl Acad. Sci. USA102(29), 10345–10350 (2005).
   PubMed Web of Science ®Google Scholar
• Whitworth AJ, Theodore DA, Greene JC et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson’s disease. Proc. Natl Acad. Sci. USA102(22), 8024–8029 (2005).
   PubMed Web of Science ®Google Scholar
• Pesah Y, Pham T, Burgess H et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development131(9), 2183–2194 (2004).
   PubMed Web of Science ®Google Scholar
• Wang C, Lu R, Ouyang X et al. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J. Neurosci.27(32) 8563–8570 (2007).
   PubMed Web of Science ®Google Scholar
• Doss-Pepe EW, Chen L, Madura K. α-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J. Biol. Chem.280(17), 16619–16624 (2005).
   PubMed Web of Science ®Google Scholar
• Hampe C, Ardila-Osorio H, Fournier M, Brice A, Corti O. Biochemical analysis of Parkinson’s disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet.15(13), 2059–2075 (2006).
   PubMed Web of Science ®Google Scholar
• Lim KL, Chew KC, Tan JM et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci.25(8), 2002–2009 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuda N, Kitami T, Suzuki T et al. Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J. Biol. Chem.281(6), 3204–3209 (2006).
   PubMed Web of Science ®Google Scholar
• Arnason T, Ellison MJ. Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain. Mol. Cell. Biol.14(12), 7876–7883 (1994).
   PubMedGoogle Scholar
• Fisk HA, Yaffe MP. A role for ubiquitination in mitochondrial inheritance in Saccharomyces cerevisiae. J. Cell. Biol.145(6), 1199–1208 (1999).
   PubMed Web of Science ®Google Scholar
• Galan JM, Haguenauer-Tsapis R. Ubiquitin lys63 is involved in ubiquitination of a yeast plasma membrane protein. EMBO J.16(19), 5847–5854 (1997).
   PubMedGoogle Scholar
• Spence J, Sadis S, Haas AL, Finley D. A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol.15(3), 1265–1273 (1995).
   PubMed Web of Science ®Google Scholar
• Wang C, Deng L, Hong M et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature412(6844), 346–351 (2001).
   PubMed Web of Science ®Google Scholar
• Fallon L, Belanger CM, Corera AT et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell. Biol.8(8), 834–842 (2006).
   PubMed Web of Science ®Google Scholar
• Olzmann JA, Li L, Chudaev MV et al. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J. Cell. Biol.178(6), 1025–1038 (2007).
   PubMed Web of Science ®Google Scholar
• Hayashi S, Wakabayashi K, Ishikawa A et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord.15(5), 884–888 (2000).
   PubMed Web of Science ®Google Scholar
• Mori H, Kondo T, Yokochi M et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology51(3), 890–892 (1998).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ohama E, Suzuki S et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology44(3 Pt 1), 437–441 (1994).
   PubMed Web of Science ®Google Scholar
• Lim KL, Dawson VL, Dawson TM. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson’s and other conformational diseases? Neurobiol. Aging27(4), 524–529 (2006).
   Google Scholar
• Fortun J, Dunn WA Jr, Joy S, Li J, Notterpek L. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J. Neurosci.23(33), 10672–10680 (2003).
   PubMed Web of Science ®Google Scholar
• Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell. Biol.10(12), 524–530 (2000).
   PubMed Web of Science ®Google Scholar
• Anglade P, Vyas S, Javoy–Agid F et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol. Histopathol.12(1), 25–31 (1997).
   PubMed Web of Science ®Google Scholar
• Cuervo AM. Autophagy in neurons: it is not all about food. Trends Mol. Med.12(10), 461–464 (2006).
   PubMed Web of Science ®Google Scholar
• Levine B, Yuan J. Autophagy in cell death: an innocent convict? J. Clin. Invest.115(10), 2679–2688 (2005).
   PubMed Web of Science ®Google Scholar
• Hara T, Nakamura K, Matsui M et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature441(7095), 880–884 (2006).
   Google Scholar
• Komatsu M, Waguri S, Chiba T et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature441(7095), 885–889 (2006).
   Google Scholar
• Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. α-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem.278(27), 25009–25013 (2003).
   PubMed Web of Science ®Google Scholar
• Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science305(5688), 1292–1295 (2004).
   PubMed Web of Science ®Google Scholar
• Ramirez A, Heimbach A, Grundemann J et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet.38(10), 1184–1191 (2006).
   PubMed Web of Science ®Google Scholar
• Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N. Engl. J. Med.351(19), 1972–1977 (2004).
   PubMed Web of Science ®Google Scholar
• Feany MB. New genetic insights into Parkinson’s disease. N. Engl. J. Med.351(19), 1937–1940 (2004).
   Google Scholar
• Pandey UB, Nie Z, Batlevi Y et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature447(7146), 859–863 (2007).
   PubMed Web of Science ®Google Scholar